Trial Profile

Phase 1 Study of Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MF 300 (Primary)
Indications Sarcopenia
Focus Adverse reactions; First in man
Sponsors Epirium Bio

Most Recent Events

12 Mar 2026 According to an Epirium Bio media release, data from this study will be presented at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference (ICFSR) 2026, taking place March 10-12 in Washington, DC.
27 Jan 2026 According to an Epirium Bio media release, company announced outcomes from its Type C (End-of-Phase 1) meeting with the Food and Drug Administration (FDA). Epirium has received written feedback from the FDA on its Phase 2b trial plan to evaluate MF-300, an oral 15-PGDH enzyme inhibitor for the treatment of age-related sarcopenia.
23 Jan 2026 Status changed to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com